 "Cipla's Indore plant cleared by FDA")
Cipla Limited on Wednesday announced that it has received Establishment Inspection Report (EIR) from the US FDA for its Indore facility indicating formal closure of the US FDA inspection conducted in July/August, 2015.
The FDA had made adverse observations in its inspection known as Form 483.
US market contributes 8 percent to its revenue and the company plans to step up its presence increasing sales of its front end labels and recent $ 550 million acquisition of InvaGen Pharmaceuticals and Exelan Pharmaceuticals.
